#ovarian cancer

3 stories

#business #agenus #bal #bot #breast cancer #cancer symptoms #cdk2 inhibitors #checkpoint immunotherapy #clinical trials #doctor #durham #hidden signs

Durham's Incyclix Bio Raises $52M for Gentler Cancer Therapies
Incyclix Bio secures $52M to develop less toxic cancer treatments for breast and ovarian cancers.
Dealroom · 1m
Agenus Reports 48% Survival in Ovarian Cancer Trial
Agenus shows 48% three-year survival for ovarian cancer patients with BOT+BAL combo after multiple treatments.
Financialpost · 1m
Hidden signs of ovarian cancer
Survivor and doctor reveal early ovarian cancer symptoms.
ABC7 New York · 1m